Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG

I M H Soenderstrup, A V Laenkholm, M B Jensen, J O Eriksen, A M Gerdes, T V O Hansen, T A Kruse, M J Larsen, I S Pedersen, M Rossing, M Thomassen, B Ejlertsen

Publikation: Bidrag til tidsskriftKonferenceartikel i tidsskriftForskningpeer review

18 Citationer (Scopus)


BACKGROUND: In breast cancer (BC) patients a cancer predisposing BRCA1/2 mutation is associated with adverse tumor characteristics, risk assessment and treatment allocation. We aimed to estimate overall- (OS) and disease-free survival (DFS) according to tumor characteristics and treatment among women who within two years of definitive surgery for primary BC were shown to carry a mutation in BRCA1/2 .

MATERIAL AND METHODS: From the clinical database of the Danish Breast Cancer Group we included 141 BRCA1 and 96 BRCA2 BC patients. Estrogen receptor and HER2 status were centrally reviewed on paraffin-embedded tumor tissue. Information on risk reducing surgery was obtained from the Danish Pathology and Patient Registries and included as time-dependent variables in Cox proportional hazard models.

RESULTS: Ten-year OS and DFS for BRCA1 BC patients were 78% (95% CI 69-85) and 74% (95% CI 64-81). Ten-year OS and DFS for BRCA2 BC were 88% (95% CI 78-94) and 84% (95% CI 74-91). BRCA1 BC patients as compared to BRCA2 BC patients had a higher risk of BC relapse or non-breast cancer within ten years of follow-up, independent of ER status (adjusted HR 2.78 95% CI 1.28-6.05, p = .01), but BRCA mutation was not associated with OS (adjusted HR 1.98, 95% CI 0.87-4.52, p = .10). In multivariate analysis, including both BRCA1 and BRCA2 carriers, no chemotherapy was associated with a higher risk of death (adjusted OS HR 3.58, 95% CI 1.29-9.97, p = .01) and risk reducing contralateral mastectomy (RRCM) was associated with a significantly reduced risk of death (adjusted OS HR 0.42, 95% CI =0.21-0.84, p = .01).

CONCLUSION: Difference in OS between BRCA1 and BRCA2 BC patients could be ascribed to tumor-biology. BRCA1 BC patients may have a shorter ten-year DFS than BRCA2 BC patients. Chemotherapy and risk reducing contralateral mastectomy reduce mortality for both BRCA1 and BRCA2 BC patients.

TidsskriftActa Oncologica
Udgave nummer1
Sider (fra-til)95-101
Antal sider7
StatusUdgivet - 2018
Begivenhed16th Acta Oncologica Symposium - Aarhus, Danmark
Varighed: 18 jan. 201819 jan. 2018


Konference16th Acta Oncologica Symposium


Dyk ned i forskningsemnerne om 'Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG'. Sammen danner de et unikt fingeraftryk.